Laufer Stefan A, Margutti Simona
Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Eberhard Karls University of Tuebingen, Auf der Morgenstelle 8, 72076 Tuebingen, Germany.
J Med Chem. 2008 Apr 24;51(8):2580-4. doi: 10.1021/jm701343f. Epub 2008 Mar 29.
SAR of N-alkylated isoxazolones as p38 MAP kinase inhibitors was realized. The data herein show the possibility of transferring the SAR study and evaluation from N-1-substituted imidazole to isoxazolones. Optimization of substituent was realized.
实现了作为p38丝裂原活化蛋白激酶抑制剂的N-烷基化异恶唑酮的构效关系研究。本文数据表明了将构效关系研究和评估从N-1-取代咪唑转移到异恶唑酮的可能性。实现了取代基的优化。